HIV treatment: latest news

HIV treatment resources

HIV treatment features

HIV treatment in your own words

HIV treatment news from aidsmap

More news

HIV treatment news selected from other sources

  • ViiV Healthcare and CHAI collaboration delivers second milestone with first filing with the FDA of generic dolutegravir by Aurobindo Pharma for the treatment of HIV

    ViiV Healthcare, Aurobindo Pharma, and the Clinton Health Access Initiative, Inc. (CHAI) announced today that Aurobindo Pharma has submitted an Abbreviated New Drug Application (ANDA) for dolutegravir 50mg, for Tentative Approval, to the Food and Drug Administration (FDA), for the treatment of HIV. This is the first ANDA for a generic version of dolutegravir, less than two years after FDA approval of Tivicay® (dolutegravir) for sale in the United States. Upon receiving Tentative Approval from the FDA, Aurobindo Pharma will be able to supply dolutegravir 50mg via the President’s Emergency Plan for AIDS Relief (PEPFAR) programme, following completion of required local regulatory approval process, in the licensed countries outside of the United States, as per the agreement signed between Aurobindo Pharma and ViiV Healthcare in 2014.

    26 May 2015 | ViiV Healthcare
  • Six questions about HIV/AIDS that deserve more attention

    As HIV investigators work to control and eradicate the virus worldwide, certain myths or misconceptions about the disease have been embraced, whereas other concepts with merit have been left relatively unexplored, argues American HIV/AIDS researcher Jay Levy, M.D., in a Trends in Molecular Medicine commentary. He calls on fellow researchers to continue questioning and not to lose sight of alternative strategies that could ultimately lead to a sustainable, long-term solution to HIV infection.

    15 April 2015 | Eurekalert Inf Dis
  • 'This is what it's really like to live with HIV'

    The number of young men being diagnosed with HIV has doubled in ten years; the number of new diagnoses among gay and bisexual men has reached a record high, according to the most recent data. The virus is rarely out of the news, and yet, because of continuing developments in treatment, few of us understand what life with the condition is like now. Three young men, all diagnosed in their 20s, talk about living with the virus.

    10 April 2015 | Daily Telegraph
  • Early HIV treatment and isoniazid prophylaxis: why TEMPRANO results do not yet support universal ART at CD4 >500 cells/mm3

    The TEMPRANO study presented as a late breaker oral presentation, included important information for timing of TB prophylaxis and the timing of ART in TB-endemic countries. The conclusions though do not support universally starting treatment at CD4 counts >500 or answer the primary question of the international START study.

    03 March 2015 | HIV i-Base
  • Next-Generation HIV and Hep C Treatment Plans Ahead at CROI

    New research on the treatment and prevention of HIV/AIDS and hepatitis C will dominate the Conference on Retroviruses and Opportunistic Infections (CROI) 2015, which this year adds a special session on Ebola.

    13 February 2015 | Medscape (free registration required)
  • Dutrebis, New HIV Drug, Approved by FDA, but Not Commercially Available

    The new combination contains 150 mg of lamivudine (3TC, Epivir) and 300 mg of raltegravir (Isentress). Despite the FDA approval, the drug manufacturer, Merck Pharmaceuticals, announced that they would not be making Dutrebis commercially available in the U.S. at this time.

    11 February 2015 | The Body Pro
  • CROI 2015 Preview: New Research on HIV, Hepatitis C and Ebola

    It's the beginning of the year, which means another Conference on Retroviruses and Opportunistic Infections (CROI) is upon us. This year's CROI takes place in Seattle and should prove to be another exciting conference as new research is presented.

    11 February 2015 | The Body Pro
  • US: A Call for Improved HIV-Related Scientific Literacy on the Front Lines

    Poor scientific literacy among non-medical members of the HIV-related workforce must be addressed in order to better fight the epidemic. Many workers are unfamiliar with biomedical prevention of HIV—using antiretrovirals to reduce the risk of HIV transmission—and don’t know enough about how and when such an intervention should be used.

    10 February 2015 | AIDSMeds
  • Déjà Vu – Claims of HIV Cures and Re-Treading Old Ground

    A few days ago while in Abuja, I was surprised to hear the news presenter announce that a Federal High Court had “lifted the ban” on Dr Abalaka’s “vaccine” against HIV. I was struck by a number of things – an abiding discomfort at the quality of reporting on science and health matters in the Nigerian media; a sense of guilt that, in failing to tell our stories, younger Nigerians are at risk of repeating missteps of the past; and a fear that many, misled by the news item, may put their lives at risk.

    28 January 2015 | Nigeria Health Watch
  • Why scientific AIDS explanations struggle in townships

    HIV/AIDS educators often seem to enjoy raising an eyebrow at outlandish beliefs over the disease. But in doing so they fail to realise that the joke is on them – these ideas continue to hold sway despite their best efforts.

    26 January 2015 | Africa Check
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.